S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University
SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- The inaugural S2S China Symposium has announced the finalists of its 2026 program. Co-hosted by RA Capital Management and Qiming Venture Partners, S2S China is the China chapter of Science2Startup, an...
Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its...
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its...